EDIT

Editas Medicine, Inc. (EDIT) | Rumor.io

Editas Medicine

EDIT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,945

Bullish sentiment (50-day avg)81%

Price to earnings ratio-1.4

Market capitalization385.5M

Earnings per share-0.66

Dividend yield (TTM)—

Revenue (annual)40.5M

Net income (annual)-160.1M

Social

What share of all stock conversation is about EDIT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

May 27

Editas Medicine's ($EDIT) genome editing technology is gaining broad social acceptance, with some predicting advocacy for germline editing in 5 years.
The company's 401 therapy shows promise, with a recent Lilly announcement validating the broader in vivo cardiovascular editing field and raising the bar for EDIT-401 clinically.
Editas Medicine's secondary offering will add 55.6M shares, diluting EPS but reducing future Net Loss Per Share, while fresh cash will be deployed into short-term, yield-bearing instruments.

Generated by AI

Sentiment

Of the messages about EDIT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	75% -25	75% -18.75	85.62% +22.5
Bearish	0%	25% new	25% +18.75	14.38% -22.5

Bullish· Mar 9

Editas Medicine's revenue has exceeded expectations, driven by growth in its therapeutic area.
The company's strong cash position, with a runway into Q3 2027, provides a solid foundation for future growth.
Editas's partnership with BMY is quietly generating revenue, which could lead to significant upside in the stock.

Bearish· Feb 20

Editas Medicine's market capitalization has decreased significantly, from $11 to its current price.
The stock's recent price action appears to be a result of selling calls and buying puts at the top, indicating a bearish sentiment.
The company's ability to execute a buyout or reach the clinic with its CAS9/12 technology is still pending, and bears are waiting for confirmation to cover their short positions.

Generated by AI

Topics

Of the messages about EDIT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	8.77%
Announcements	—	—	100%	74.98%
Macro	—	—	0%	1.87%
Analysts	—	—	0%	0.89%
Controversies	—	—	0%	12.92%
Earnings	—	—	0%	0.57%

Analysts· Sep 10

Oppenheimer analyst Jay Olson upgraded Editas Medicine (EDIT) from Perform to Outperform and raised the price target from $42 to $80.
The upgrade was made ahead of trial data for a rare eye disease, which may have contributed to the decision.
The new price target of $80 represents a significant increase from the previous target of $42.

Announcements· Jan 3

Editas Medicine, Inc. (EDIT) is making huge strides in gene editing, potentially revolutionizing the healthcare market in the coming years.
Companies like EDIT and CRSP are poised for massive growth with CRISPR technologies, transforming the biotech industry.
Gene therapy is making waves in the healthcare sector, with companies like EDIT and CRSP at the forefront of this revolution.

Technical Analysis· Mar 9

The Editas Medicine ($EDIT) chart is forming a base after a pullback, with a potential breakout above the recent high.
A significant increase in buying activity is causing a strong price movement, indicating real momentum in the stock.
If $EDIT clears the recent high, traders may rotate back into the stock, driven by sector chatter and a growing interest in genome editing names.

Generated by AI

Community

Of the messages about EDIT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	84.62%	39.02%	62.87%
Newcomers	0%	15.38%	60.98%	37.13%

Regulars· Oct 27

Editas Medicine's royalty dispute with NTLA could be a significant issue, potentially affecting their stock price.
The company may consider pivoting to shorter CRISPR proteins as a potential solution to address their current challenges.
The regulars are concerned about the potential risks to Editas Medicine's program, specifically the royalty dispute and its implications.

Newcomers· Mar 9

Newcomers are taking note of Editas Medicine's strong cash position, which has contributed to the company's success in beating Q4 loss estimates.
Editas Medicine's revenue growth in the area of reverse-transit therapy is being highlighted as a key factor in the company's stock price increase.
Investors are considering Editas Medicine as a high-risk, high-reward play due to its involvement in gene-editing technology.

Generated by AI

News

Editas stock raised to Buy at Guggenheim (EDIT:NASDAQ)

6d agoSeeking Alpha

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On

U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.

6d agoBenzinga

This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Microsoft (NASDAQ:MSF

Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.

6d agoBenzinga

Why is Editas Medicine stock rallying today?

6d agoInvesting.com

Guggenheim upgrades Editas Medicine stock rating on gene editing therapy

7d agoInvesting.com

Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5

Editas Medicine (EDIT) has an average rating of overweight and mean price target of $4.88, according

7d agoYahoo Finance

Also Discussed

Investors talking about EDIT also mention

#	Name	Attention
1	Intellia Therapeutics, Inc.NTLA	0%+0
2	CRISPR Therapeutics AGCRSP	0%-0.01
3	Beam Therapeutics IncBEAM	0.02%+0.02
4	Caribou Biosciences, Inc.CRBU	0%new
5	SGMO - Sangamo Therapeutics, Inc.	——
6	VERV - Verve Therapeutics, Inc.	——
7	Cellectis S.A. ADRCLLS	0%new
8	Fate Therapeutics Inc.FATE	0%new
9	Vertex Pharmaceuticals Incorporated Common StockVRTX	0%-0.01
10	Twist Bioscience CorporationTWST	0%-0.02

Editas Medicine, Inc.

Healthcare
Biotechnology

Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company’s work centers on CRISPR-based technologies, including Cas9 and Cas12a, which it uses to design precise therapies for genetically driven conditions. Its current development efforts include in vivo and ex vivo programs aimed at areas such as hematology, cardiovascular disease, and other severe disorders with limited treatment options. Editas Medicine also maintains collaborations and intellectual property positions that support its research platform and pipeline. Headquartered in Cambridge, Massachusetts, the company plays a specialized role in the gene editing market by advancing experimental medicines intended to address diseases at the DNA level.

Website

Location

11 Hurley Street

Cambridge, MA, 02141

United States

Social

What share of all stock conversation is about EDIT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

May 27

Editas Medicine's ($EDIT) genome editing technology is gaining broad social acceptance, with some predicting advocacy for germline editing in 5 years.
The company's 401 therapy shows promise, with a recent Lilly announcement validating the broader in vivo cardiovascular editing field and raising the bar for EDIT-401 clinically.
Editas Medicine's secondary offering will add 55.6M shares, diluting EPS but reducing future Net Loss Per Share, while fresh cash will be deployed into short-term, yield-bearing instruments.

Generated by AI

Sentiment

Of the messages about EDIT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	75% -25	75% -18.75	85.62% +22.5
Bearish	0%	25% new	25% +18.75	14.38% -22.5

Bullish· Mar 9

Editas Medicine's revenue has exceeded expectations, driven by growth in its therapeutic area.
The company's strong cash position, with a runway into Q3 2027, provides a solid foundation for future growth.
Editas's partnership with BMY is quietly generating revenue, which could lead to significant upside in the stock.

Bearish· Feb 20

Editas Medicine's market capitalization has decreased significantly, from $11 to its current price.
The stock's recent price action appears to be a result of selling calls and buying puts at the top, indicating a bearish sentiment.
The company's ability to execute a buyout or reach the clinic with its CAS9/12 technology is still pending, and bears are waiting for confirmation to cover their short positions.

Generated by AI

Topics

Of the messages about EDIT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	8.77%
Announcements	—	—	100%	74.98%
Macro	—	—	0%	1.87%
Analysts	—	—	0%	0.89%
Controversies	—	—	0%	12.92%
Earnings	—	—	0%	0.57%

Analysts· Sep 10

Oppenheimer analyst Jay Olson upgraded Editas Medicine (EDIT) from Perform to Outperform and raised the price target from $42 to $80.
The upgrade was made ahead of trial data for a rare eye disease, which may have contributed to the decision.
The new price target of $80 represents a significant increase from the previous target of $42.

Announcements· Jan 3

Editas Medicine, Inc. (EDIT) is making huge strides in gene editing, potentially revolutionizing the healthcare market in the coming years.
Companies like EDIT and CRSP are poised for massive growth with CRISPR technologies, transforming the biotech industry.
Gene therapy is making waves in the healthcare sector, with companies like EDIT and CRSP at the forefront of this revolution.

Technical Analysis· Mar 9

The Editas Medicine ($EDIT) chart is forming a base after a pullback, with a potential breakout above the recent high.
A significant increase in buying activity is causing a strong price movement, indicating real momentum in the stock.
If $EDIT clears the recent high, traders may rotate back into the stock, driven by sector chatter and a growing interest in genome editing names.

Generated by AI

Community

Of the messages about EDIT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	84.62%	39.02%	62.87%
Newcomers	0%	15.38%	60.98%	37.13%

Regulars· Oct 27

Editas Medicine's royalty dispute with NTLA could be a significant issue, potentially affecting their stock price.
The company may consider pivoting to shorter CRISPR proteins as a potential solution to address their current challenges.
The regulars are concerned about the potential risks to Editas Medicine's program, specifically the royalty dispute and its implications.

Newcomers· Mar 9

Newcomers are taking note of Editas Medicine's strong cash position, which has contributed to the company's success in beating Q4 loss estimates.
Editas Medicine's revenue growth in the area of reverse-transit therapy is being highlighted as a key factor in the company's stock price increase.
Investors are considering Editas Medicine as a high-risk, high-reward play due to its involvement in gene-editing technology.

Generated by AI

Editas Medicine

Social

May 27

Bullish· Mar 9

Bearish· Feb 20

Analysts· Sep 10

Announcements· Jan 3

Technical Analysis· Mar 9

Regulars· Oct 27

Newcomers· Mar 9

Editas stock raised to Buy at Guggenheim (EDIT:NASDAQ)

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On

This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Microsoft (NASDAQ:MSF

Why is Editas Medicine stock rallying today?

Guggenheim upgrades Editas Medicine stock rating on gene editing therapy

Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5

Also Discussed

Editas Medicine, Inc.

Company Information

Location

Editas stock raised to Buy at Guggenheim (EDIT:NASDAQ)

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On

This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Microsoft (NASDAQ:MSF

Why is Editas Medicine stock rallying today?

Guggenheim upgrades Editas Medicine stock rating on gene editing therapy

Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5

Also Discussed

Social

May 27

Bullish· Mar 9

Bearish· Feb 20

Analysts· Sep 10

Announcements· Jan 3

Technical Analysis· Mar 9

Regulars· Oct 27

Newcomers· Mar 9